Get more replies from employers
Send a job-specific resume in minutes.
Aphios Corporation, a clinical-stage biotechnology company, seeks a Fractional Controller to strengthen financial reporting, internal controls, and audit readiness as it advances toward public markets.
This hands-on senior role targets an experienced Controller, CPA, or senior accounting professional who thrives in a biotech setting and can establish scalable processes while partnering with finance, audits, and external advisors during pre-IPO activities.
Fractional Controller – Biotechnology / Pre-IPO
Aphios CorporationNorth Reading, Massachusetts Area | Fractional / ConsultingJob Code: APH-2605
Aphios Corporation, a clinical-stage biotechnology company advancing a diversified portfolio of therapeutic products and proprietary platform technologies, is seeking an experienced Fractional Controller to strengthen the Company’s accounting, financial reporting, internal controls, and audit readiness as Aphios advances its clinical programs, strategic partnerships, financing activities, and planned path toward the public markets.
This is a hands-on senior accounting position suited for an experienced Controller, Assistant Controller, CPA, or senior accounting professional who is comfortable working with an entrepreneurial biotechnology company while establishing the financial discipline and reporting infrastructure expected of a substantially larger organization.
The successful candidate should have strong accounting and financial reporting experience and familiarity with Sage accounting software or another accounting system capable of supporting GAAP-compliant financial reporting and robust internal controls.
Experience with NIH/SBIR funding, biotechnology accounting, financial audits, SEC reporting, IPO preparation, or public-company accounting is highly desirable.
Aphios has a significant history of federally funded research and development. Experience with NIH, SBIR/STTR, or other federal grant accounting would therefore be particularly valuable.
Relevant experience may include:
As Aphios strengthens its financial infrastructure in anticipation of future capital formation and potential entry into the public markets, additional value would be placed on experience involving one or more of the following:
This is initially envisioned as a Fractional or consulting position, with hours and structure determined based on the candidate’s experience and Aphios’ evolving requirements.
The role could expand as the Company’s clinical programs, financing activities, strategic partnerships, and public-market preparations progress.
Aphios Corporation is advancing a portfolio that includes a planned Phase 3 clinical program for Zindol®, planned Phase 2b programs in opioid addiction and chronic epilepsy, and additional therapeutic programs progressing through IND-enabling development.
Aphios combines clinical-stage assets with proprietary pharmaceutical and nanotechnology platforms and is pursuing strategic partnerships, institutional financing, and longer-term public-market opportunities.